CLSD

Clearside Biomedical, Inc. [CLSD] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CLSD Stock Summary

Top 10 Correlated ETFs

CLSD


Top 10 Correlated Stocks

CLSD


In the News

08:22 26 Mar 2023 CLSD

Clearside Biomedical, Inc. (CLSD) Q4 2022 Earnings Call Transcript

Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive Officer Charles Deignan - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham & Company Jonathan Wolleben - JMP Securities Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by and welcome to the Clearside Biomedical Fourth Quarter 2022 Financial Results and Corporate Update Conference Call.

07:49 26 Mar 2023 CLSD

Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

07:05 26 Mar 2023 CLSD

Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023

ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2022 financial results will be reported on Thursday, March 9, 2023 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

04:41 26 Mar 2023 CLSD

Clearside Biomedical, Inc. (CLSD) Q3 2022 Earnings Call Transcript

Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2022 Earnings Call Transcript November 9, 2022 8:30 AM ET Company Representatives George Lasezkay - Chief Executive Officer Tom Ciulla - Chief Medical Officer, Chief Development Officer Charles Deignan - Chief Financial Officer Dr. Arshad Khanani - Managing Partner at Sierra Eye Associates, Clinical Associate Professor at the University of Nevada Jenny Kobin - Investor Relations Conference Call Participants Andreas Argyrides - Wedbush Annabel Samimy - Stifel John Wolleben - JMP Securities Yi Chen - H.C. Wainwright Serge Belanger - Needham & Company Mayank Mamtani - B.

04:05 26 Mar 2023 CLSD

Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results

Webcast and Conference Call on Wednesday, November 9, 2022 at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Arshad Khanani, M.D. Webcast and Conference Call on Wednesday, November 9, 2022 at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Arshad Khanani, M.D.

07:05 26 Mar 2023 CLSD

Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022

ALPHARETTA, Ga., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2022 financial results will be reported on Wednesday, November 9, 2022 before the open of the financial markets. Management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update.

07:05 26 Mar 2023 CLSD

Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November 2022 CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November 2022

07:05 26 Mar 2023 CLSD

Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022

ALPHARETTA, Ga., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview and participate in an industry panel virtually during the Ophthalmology Futures Retina Forum 2022 on August 31, 2022.

02:47 26 Mar 2023 CLSD

Clearside Biomedical Inc (CLSD) CEO George Lasezkay on Q2 2022 Results - Earnings Call Transcript

Clearside Biomedical Inc (NASDAQ:CLSD ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Jenny Kobin - Head of IR George Lasezkay - President, CEO and Director Tom Ciulla - Chief Medical Officer and Chief Development Officer Charles Deignan - CFO Conference Call Participants Stacy Lee - Stifel Rohit Bhasin - Needham & Company Yi Chen - H.C. Wainwright William Wood - B.

07:05 26 Mar 2023 CLSD

Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022

ALPHARETTA, Ga., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in the following investor conferences in August 2022:

CLSD Financial details

Company Rating
Strong Buy
Market Cap
59.52M
Income
-32.95K
Revenue
731K
Book val./share
0.18
Cash/share
0.8
Dividend
-
Dividend %
-
Employees
34
Optionable
No
Shortable
Yes
Earnings
09 May 2023
P/E
-12.76
Forward P/E
-
PEG
-
P/S
2.59
P/B
3.15
P/C
1.21
P/FCF
-20.82
Quick Ratio
10.28
Current Ratio
10.54
Debt / Equity
3.84
LT Debt / Equity
0.09
-
-
EPS (TTM)
0
EPS next Y
-
EPS next Q
-
EPS this Y
-108.7%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-81.71%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-400%
-
-
-
-
SMA20
-23.66%
SMA50
-32.89%
SMA100
-8.26%
Inst Own
15.17%
Inst Trans
-4.99%
ROA
-8%
ROE
-16%
ROC
-0.07%
Gross Margin
98%
Oper. Margin
-16%
Profit Margin
-20%
Payout
-
Shs Outstand
61.36M
Shs Float
53.18M
-
-
-
-
Target Price
-
52W Range
0.93-2.54
52W High
-
52W Low
-
RSI
34.62
Rel Volume
0.31
Avg Volume
216.79K
Volume
67.91K
Perf Week
-1.02%
Perf Month
-28.68%
Perf Quarter
-14.16%
Perf Half Y
-15.65%
-
-
-
-
Beta
1.96387
-
-
Volatility
0.03%, 0.14%
Prev Close
-4.9%
Price
0.97
Change
-3.96%

CLSD Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
00.060.170.640
Net income per share
-2.69-0.81-0.390.010
Operating cash flow per share
-2.58-0.71-0.28-0.230
Free cash flow per share
-2.58-0.71-0.28-0.230
Cash per share
1.330.590.370.650.8
Book value per share
0.770.290.190.820.18
Tangible book value per share
0.770.290.190.820.18
Share holders equity per share
0.770.290.190.820.18
Interest debt per share
0.320.140.040.010.02
Market cap
32.88M110.7M127.43M127.89M67.43M
Enterprise value
34.82M93.61M112.12M98.13M20.46M
P/E ratio
-0.4-3.6-7340.14-2.05K
Price to sales ratio
1.1K50.9416.144.320
POCF ratio
-0.42-4.09-9.71-11.92-5.05K
PFCF ratio
-0.41-4.09-9.67-11.92-4.95K
P/B Ratio
1.399.9214.543.376.36
PTB ratio
1.399.9214.543.376.36
EV to sales
1.16K43.0814.23.320
Enterprise value over EBITDA
-0.42-3.06-6.22177.13-690.91
EV to operating cash flow
-0.44-3.46-8.55-9.14-1.53K
EV to free cash flow
-0.44-3.46-8.51-9.14-1.5K
Earnings yield
-2.52-0.28-0.1400
Free cash flow yield
-2.41-0.24-0.1-0.080
Debt to equity
0.871.41.20.133.84
Debt to assets
0.460.580.550.110.79
Net debt to EBITDA
-0.020.560.85-53.721.59K
Current ratio
4.12.311.829.088.54
Interest coverage
0000-9.07
Income quality
0.960.880.72-28.550.41
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
489.477.741.360.390
Research and developement to revenue
2.28K7.211.910.630
Intangibles to total assets
00000
Capex to operating cash flow
00000.02
Capex to revenue
-2.93-0.01-0.0100
Capex to depreciation
-0.47-0.12-0.310-1.7
Stock based compensation to revenue
159.52.120.460.170
Graham number
6.832.31.290.390.05
ROIC
-3.921.541.040.030
Return on tangible assets
-1.88-1.15-0.940.010
Graham Net
0.660.180.140.710.13
Working capital
32.47M14.32M8.18M37.5M43.62M
Tangible asset value
23.62M11.16M8.76M37.98M10.61M
Net current asset value
22.44M9.6M7.56M37.21M8.71M
Invested capital
0.420.490.230.020.12
Average receivables
0005M5M
Average payables
6.13M4.07M1.64M1.47M995.5K
Average inventory
00000
Days sales outstanding
000123.420
Days payables outstanding
00001.88M
Days of inventory on hand
00000
Receivables turnover
0002.960
Payables turnover
00000
Inventory turnover
00000
ROE
-3.51-2.76-2.080.010
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric History 2021-12-312022-03-312022-06-302022-09-30 2022-12-31
Revenue per share
0.370.010.0100
Net income per share
0.31-0.13-0.13-0.130.39
Operating cash flow per share
0.080.06-0.09-0.10.13
Free cash flow per share
0.080.06-0.09-0.110.13
Cash per share
0.510.570.480.890.8
Book value per share
0.640.530.420.310.18
Tangible book value per share
0.640.530.420.310.18
Share holders equity per share
0.640.530.420.310.18
Interest debt per share
0.010.010.010.030
Market cap
164.09M137.55M88.42M68.01M67.43M
Enterprise value
134.33M103.77M59.89M15.04M20.46M
P/E ratio
2.19-4.5-2.83-2.170.73
Price to sales ratio
7.53396.39230.2600
POCF ratio
32.4735.53-16.24-10.998.71
PFCF ratio
32.4735.53-16.24-10.738.54
P/B Ratio
4.324.343.53.676.36
PTB ratio
4.324.343.53.676.36
EV to sales
6.16299.04155.9600
Enterprise value over EBITDA
7.16-13.66-7.7-2.320.94
EV to operating cash flow
26.5826.81-11-2.432.64
EV to free cash flow
26.5826.81-11-2.372.59
Earnings yield
0.11-0.06-0.09-0.120.34
Free cash flow yield
0.030.03-0.06-0.090.12
Debt to equity
0.130.140.2223.84
Debt to assets
0.110.120.180.670.79
Net debt to EBITDA
-1.594.453.678.16-2.15
Current ratio
9.088.495.5610.548.54
Interest coverage
000-5.18-17.14
Income quality
0.27-0.510.70.790.33
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.149.967.2700
Research and developement to revenue
0.1813.0714.1400
Intangibles to total assets
00000
Capex to operating cash flow
0000.030.02
Capex to revenue
00000
Capex to depreciation
000-3.97-1.26
Stock based compensation to revenue
0.063.773.5300
Graham number
2.121.231.110.951.24
ROIC
-0.990.220.260.13-0.48
Return on tangible assets
0.44-0.21-0.25-0.140.45
Graham Net
0.550.50.390.270.13
Working capital
37.5M31.12M24.6M49.66M43.62M
Tangible asset value
37.98M31.7M25.25M18.55M10.61M
Net current asset value
37.21M30.92M24.49M17.72M8.71M
Invested capital
0.020.020.020.020.12
Average receivables
5M5M61.5K123K61.5K
Average payables
858.5K1.17M2.02M2.19M1.39M
Average inventory
00000
Days sales outstanding
41.29028.8300
Days payables outstanding
0000463.24K
Days of inventory on hand
00000
Receivables turnover
2.1803.1200
Payables turnover
00000
Inventory turnover
00000
ROE
0.49-0.24-0.31-0.422.19
Capex per share
00000

CLSD Frequently Asked Questions

What is Clearside Biomedical, Inc. stock symbol ?

Clearside Biomedical, Inc. is a US stock , located in Alpharetta of Ga and trading under the symbol CLSD

What is Clearside Biomedical, Inc. stock quote today ?

Clearside Biomedical, Inc. stock price is $0.97 today.

Is Clearside Biomedical, Inc. stock public?

Yes, Clearside Biomedical, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap